

[Valganciclovir](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.4. Antiviral medicines 6.4.3. Other antivirals](#)

ATC codes: [J05AB14](#)

EMLc

Indication

Cytomegaloviral retinitis ICD11 code: [9B72.00](#)

INN

Valganciclovir

Medicine type

Chemical agent

List type

Core (EML)

Complementary (EMLc)

Formulations

Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution (EMLc)

Oral > Solid > tablet: 450 mg (as hydrochloride)

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Valganciclovir](#)

DrugBank

[Valganciclovir](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.